Eisai acquires Chinese generics maker

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Eisai acquires Chinese generics maker

INICIO/Noticias Farmacéuticas | Posted 22/01/2016 0 Post your comment

Japanese pharmaceutical company Eisai announced on 28 December 2015 that it had acquired Chinese generics maker Liaoning TianYi Biological Pharmaceutical.

The acquisition marks a move by Eisai into the Chinese generics market, and also strengthens the company’s presence in China, where it has been doing business for over 25 years. The acquisition, says Eisai, will enable the company ‘to fulfill an even wider range of medical needs in China’ and to provide ‘a stable supply of high quality generic pharmaceuticals’.

The trading name of Liaoning TianYi Biological Pharmaceutical has been changed to Eisai (Liaoning) Pharmaceutical (Eisai Liaoning) and the company has become a wholly-owned subsidiary of Eisai China Holdings.

Eisai Liaoning manufactures and markets both generics and active pharmaceutical ingredients, and has manufacturing approval for approximately 90 pharmaceutical products covering a wide range of diseases, including immune modulators, traditional Chinese medicines and treatments for inflammation and pain relief, dementia, gastritis, intestinal disorders, diabetes as well as chronic arterial occlusion. In addition, Eisai Liaoning possesses the latest production line and technology that is compliant with China’s Good Manufacturing Practice (GMP) standards to enable the handling of various different formulations, such as tablets, capsules, granules, liquid medicines, and freeze-dried injectables.

The Chinese pharmaceutical market is the second largest in the world after the US. Despite China experiencing a slowdown in economic growth, the Chinese pharmaceutical market is still forecasted to maintain strong growth due to the rapidly ageing population and the government’s policies to improve access to medicines. China’s healthcare reform of 2009 aims to offer affordable medical care to more than 90% of its residents by the end of 2011 and to the entire population by 2020 [1].

China follows the Thai and Indian route to affordable drugs

Reference
1. GaBI Online - Generics and Biosimilars Initiative. China’s Healthcare reform in 2010 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Jan 22]. Available from: www.gabionline.net/Policies-Legislation/China-s-healthcare-reform-in-2010

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Eisai